Ryuma Tokunaga1, Shu Cao2, Madiha Naseem3, Jae Ho Lo3, Francesca Battaglin4, Alberto Puccini3, Martin D Berger3, Shivani Soni3, Joshua Millstein2, Wu Zhang3, Sebastian Stintzing5, Fotios Loupakis6, Chiara Cremolini7, Volker Heinemann5, Alfredo Falcone7, Heinz-Josef Lenz3. 1. Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA. Electronic address: rtokunag@usc.edu. 2. Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA. 3. Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA. 4. Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA; Department of Clinical and Experimental Oncology, Medical Oncology Unit 1, Veneto Institute of Oncology, Scientific Institute for Research and Healthcare, Padua, Italy. 5. Comprehensive Cancer Center, Ludwig-Maximilian-University of Munich, Munich, Germany. 6. Department of Clinical and Experimental Oncology, Medical Oncology Unit 1, Veneto Institute of Oncology, Scientific Institute for Research and Healthcare, Padua, Italy. 7. Department of Medical Oncology, University of Pisa, Pisa, Italy.
Abstract
BACKGROUND: Adenosine has an immunosuppressive and angiogenic modulation of the tumor microenvironment. The present study explored the efficacy of single nucleotide polymorphisms (SNPs) in adenosine-related molecules for patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. PATIENTS AND METHODS: We analyzed genomic DNA extracted from 451 samples from 3 independent cohorts: a discovery cohort of 107 patients treated with FOLFIRI (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) plus bevacizumab in FIRE-3 (ClinicalTrials.gov identifier, NCT00433927); a validation cohort of 215 patients with FOLFIRI plus bevacizumab in TRIBE (ClinicalTrials.gov identifier, NCT00719797); and a control cohort of 129 patients treated with FOLFIRI plus cetuximab in FIRE-3. The relationship between the selected SNPs and clinical outcomes was analyzed. RESULTS: In the discovery cohort, patients with any C allele in CD39 rs11188513 had significantly shorter median progression-free survival compared with those with the T/T variant (11.3 vs. 13.1 months; hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.04-2.77; P = .022) on univariate analysis. Also, their overall survival (OS) was shorter (27.4 vs. 49.9 months; HR, 2.10; 95% CI, 1.07-4.10; P = .031) on univariate and multivariable analyses. The significant association between CD39 rs11188513 and OS was confirmed in the validation cohort (25.8 vs. 31.6 months; HR, 1.53; 95% CI, 1.09-2.15; P = .013). CD73 rs2229523 and A2BR rs2015353 in the discovery cohort and CD39 rs2226163 in the validation cohort showed significant correlations with OS on univariate and multivariable analyses. None of SNPs were significant in the cetuximab control cohort. CONCLUSION: Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab.
BACKGROUND:Adenosine has an immunosuppressive and angiogenic modulation of the tumor microenvironment. The present study explored the efficacy of single nucleotide polymorphisms (SNPs) in adenosine-related molecules for patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. PATIENTS AND METHODS: We analyzed genomic DNA extracted from 451 samples from 3 independent cohorts: a discovery cohort of 107 patients treated with FOLFIRI (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) plus bevacizumab in FIRE-3 (ClinicalTrials.gov identifier, NCT00433927); a validation cohort of 215 patients with FOLFIRI plus bevacizumab in TRIBE (ClinicalTrials.gov identifier, NCT00719797); and a control cohort of 129 patients treated with FOLFIRI plus cetuximab in FIRE-3. The relationship between the selected SNPs and clinical outcomes was analyzed. RESULTS: In the discovery cohort, patients with any C allele in CD39rs11188513 had significantly shorter median progression-free survival compared with those with the T/T variant (11.3 vs. 13.1 months; hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.04-2.77; P = .022) on univariate analysis. Also, their overall survival (OS) was shorter (27.4 vs. 49.9 months; HR, 2.10; 95% CI, 1.07-4.10; P = .031) on univariate and multivariable analyses. The significant association between CD39rs11188513 and OS was confirmed in the validation cohort (25.8 vs. 31.6 months; HR, 1.53; 95% CI, 1.09-2.15; P = .013). CD73rs2229523 and A2BRrs2015353 in the discovery cohort and CD39rs2226163 in the validation cohort showed significant correlations with OS on univariate and multivariable analyses. None of SNPs were significant in the cetuximab control cohort. CONCLUSION: Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab.
Authors: Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky Journal: Proc Natl Acad Sci U S A Date: 2006-08-17 Impact factor: 11.205
Authors: Kristin Synnestvedt; Glenn T Furuta; Katrina M Comerford; Nancy Louis; Jorn Karhausen; Holger K Eltzschig; Karl R Hansen; Linda F Thompson; Sean P Colgan Journal: J Clin Invest Date: 2002-10 Impact factor: 14.808
Authors: John Stagg; Upulie Divisekera; Helene Duret; Tim Sparwasser; Michele W L Teng; Phillip K Darcy; Mark J Smyth Journal: Cancer Res Date: 2011-02-03 Impact factor: 12.701
Authors: Tobias Eckle; Lars Füllbier; Manfred Wehrmann; Joseph Khoury; Michel Mittelbronn; Juan Ibla; Peter Rosenberger; Holger K Eltzschig Journal: J Immunol Date: 2007-06-15 Impact factor: 5.422
Authors: Robert A Figler; Guoquan Wang; Susseela Srinivasan; Dae Young Jung; Zhiyou Zhang; James S Pankow; Katya Ravid; Bertil Fredholm; Catherine C Hedrick; Stephen S Rich; Jason K Kim; Kathryn F LaNoue; Joel Linden Journal: Diabetes Date: 2011-02 Impact factor: 9.461
Authors: Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson Journal: J Exp Med Date: 2007-05-14 Impact factor: 14.307
Authors: Oliver Kepp; Lucillia Bezu; Takahiro Yamazaki; Francesco Di Virgilio; Mark J Smyth; Guido Kroemer; Lorenzo Galluzzi Journal: EMBO J Date: 2021-06-14 Impact factor: 14.012